Acyl bromides
TARGETMOL CHEMICALS INC Tarloxotinib bromide 1MG
Also available in 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg and bulk. Please contact Fisher for quotes. Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2. Purity 97.15%
Selleck Chemical LLC Methylbenactyzine Bromide S4623-25mg
Methylbenactyzine Bromide (Gastrimade Noinarin Paragone Semulgin) is a kind of muscarinic cholinergic receptor antagonist with antispasmodic activity
Selleck Chemical LLC Ipratropium Bromide S1683-50mg
Ipratropium Bromide is an antagonist of M3 type muscarinic acetylcholine receptors used for the treatment of chronic obstructive pulmonary disease (COPD)
Cayman Chemical QX314 bromide Other Receptor
A membrane-impermeant lidocaine derivative that when combined with capsaicin selectively blocks sodium channels on nociceptive neurons via the TRPV1 channel; decreases the pain response without imparting numbness or paralysis associated with other local anesthetics
Medchemexpress LLC Cimetropium Bromide | 51598-60-8 | 438.36 | 10 MM * 1 ML
Cimetropium Bromide (DA-3177) is an mAChR antagonist developed for the long-term treatment of irritable bowel syndrome. This compound is intended for research use only and functions as a competitive antagonist of muscarinic-mediated contractions in isolated colonic preparations.
- Acts as a competitive antagonist of muscarinic-mediated contractions.
- Exhibits potent antimuscarinic effects on longitudinal muscle preparations.
- Effectively inhibits large bowel motility in vivo.
- Suitable for research applications related to irritable bowel syndrome.
eMolecules 10031-26-2 | Iron(III) bromide | Oakwood Chemicals295.557 | Br3Fe | 98.000 | [Fe+3].[Br-].[Br-].[Br-] | 100g | 480150192
Iron(III) bromide | Oakwood Chemicals | 10031-26-2295.557 | Br3Fe | 98.000 | [Fe+3].[Br-].[Br-].[Br-] | 100g | 480150192
Medchemexpress LLC Pinaverium bromide | 53251-94-8 | MFCD08063574 | 98.0% | 591.42 g/mol | C26H41Br2NO4 | 5 MG
Pinaverium bromide is an analytical research standard of an L-type calcium channel blocker with selectivity for the gastrointestinal tract. Supplied in small laboratory pack sizes, it is intended for analytical and pharmacological research, method development, and use as a reference material. The compound has formula C26H41Br2NO4, molecular weight 591.42 g/mol, and CAS 53251-94-8.
- Research-grade analytical standard for L-type calcium channel studies.
- Supplied in small, lab-friendly pack sizes for routine use.
- High purity suitable for analytical and pharmacological assays.
- Datasheet, safety data sheet, and certificate of analysis available on request.
- Stable bromide salt form appropriate for gastrointestinal pharmacology research.
eMolecules 5349-17-7 | 4-(Bromoacetyl)pyridine hydrobromide | Combi-Blocks | MFCD02681893 | 280.947 | C7H7Br2NO | 90.000 | Br.BrCC(=O)c1ccncc1 | 5g | 249357428
4-(Bromoacetyl)pyridine hydrobromide | Combi-Blocks | 5349-17-7 | MFCD02681893 | 280.947 | C7H7Br2NO | 90.000 | Br.BrCC(=O)c1ccncc1 | 5g | 249357428
Medchemexpress LLC Ipratropium bromide hydrate | 66985-17-9 | 99.9% | 500 MG
Ipratropium bromide hydrate is a muscarinic receptor antagonist that relaxes smooth muscle. It can be used in research for COPD (chronic obstructive pulmonary disease) and asthma.
- Muscarinic receptor antagonist
- IC50s of 2.9 nM for M1, 2 nM for M2, and 1.7 nM for M3 receptors
- Exerts toxic effects via disruption of mitochondrial membrane potential
- Increases infarct size in isolated perfused heart ischaemia/reperfusion experiments with a dose-responsive manner
- Inhibits adult rat cardiac myocyte growth after hypoxia treatment
Medchemexpress LLC Rapacuronium bromide | 156137-99-4 | MFCD00870871 | 98.0% | 677.80 g·mol⁻¹ | C37H61BrN2O4 | 10 MG
Rapacuronium bromide is a non-depolarizing aminosteroid neuromuscular blocker and an allosteric modulator of muscarinic acetylcholine receptors supplied for research use only. It is offered in solid and solution formats across multiple pack sizes and is provided at high purity.
- Non-depolarizing neuromuscular blocker and allosteric modulator of muscarinic acetylcholine receptors.
- Intended for research use only; not for human or veterinary use.
- Available in solid and DMSO solution formats for flexible experimental use.
- High purity (98.0%) suitable for analytical and preclinical studies.
- Provided with CAS number and chemical formula for traceability.
Medchemexpress LLC Aclidinium bromide | 320345-99-1 | MFCD22683690 | 99.0% | C26H30BrNO4S2 | 10MG
Aclidinium bromide is a long-acting inhaled muscarinic antagonist used in respiratory research, primarily for studies of chronic obstructive pulmonary disease (COPD) and muscarinic receptor function. Supplied as the bromide salt with characterized identity and high purity, it is intended for in vitro and preclinical pharmacology applications.
- Long-acting muscarinic antagonist for COPD and airway research.
- High purity suitable for analytical and pharmacological studies.
- Available as solid and DMSO solution formats for flexible use.
- Well-characterized chemical identity and molecular data.
- Useful as a pharmacological tool to probe muscarinic receptor-mediated bronchodilation.
Medchemexpress LLC N-benzoyl-5'-O-dmtr-2'-O-(2-methoxyethyl)-adenosine | 251647-48-0 | 99.9% | 1 ML
N-Benzoyl-5'-O-dmtr-2'-O-(2-methoxyethyl)-adenosine is an adenosine analog that primarily functions as a smooth muscle vasodilator and has also demonstrated potential in inhibiting cancer progression.
- Functions as a smooth muscle vasodilator
- Demonstrates potential in inhibiting cancer progression
Medchemexpress LLC Thonzonium bromide | 553-08-2 | 99.86% | 1 ML
Thonzonium bromide is an antibacterial agent and monocationic surface-active agent that inhibits RANKL-induced osteoclast formation and bone resorption in vitro. It prevents LPS-induced bone loss in vivo by blocking RANKL-induced activation of NF-κB, ERK, c-Fos, and NFATc1, which are crucial for osteoclast formation. Additionally, it disrupts F-actin ring formation in mature osteoclasts and inhibits proton transport in a dose-dependent manner.
- Inhibits RANKL-induced osteoclast formation
- Prevents LPS-induced bone loss in vivo
- Blocks key signaling pathways for osteoclast formation
- Disrupts F-actin ring formation in mature osteoclasts
- Inhibits proton transport